Aclaris Therapeutics Inc (NASDAQ: ACRS) shares plunged after the company released topline results from a Phase 2b study of zunsemetinib (ATI-450) in subjects with moderate to
Verve Therapeutics Inc (NASDAQ: VERV) released the first human proof-of-concept data for in vivo base editing from the ongoing heart-1 phase 1b trial of VERVE-101 from the
ImmunoPrecise Antibodies Ltd's (NASDAQ: IPA) subsidiary BioStrand has published a preprint of its white paper titled "New Paradigm for Biological Sequence Retrieval Inspired by Natural
Alzamend Neuro Inc (NASDAQ: ALZN) has submitted an investigational new drug (IND) application to the FDA for the initiation of study AL001-PTSD01, a Phase 2A plasma/brain pharmacokinetics study of AL001 for patients with post-traumatic stress disorder (PTSD).
Cantor Fitzgerald initiated coverage on NeuroPace Inc (NASDAQ: NPCE), a commercial-stage medical device company focused on drug-resistant epilepsy treatment through the company's responsive neurostimulation device (RNS).